ArticleEndocrine connections2026
Characterization of the patient profile and efficacy of empirical radioiodine therapy in differentiated thyroid cancer with biochemical evidence without identified iodine-avid structural metastatic disease.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the profile of patients and tumor features of differentiated thyroid carcinoma (DTC) with biochemical evidence without structurally demonstrable metastatic disease in the postoperative follow-up, regarding the response to empirical radioiodine therapy (RIT). Methods: A retrospective study of 196 patients with DTC followed up at a tertiary service from 1990 to 2018 was performed. All of them presented negative diagnostic whole-body scan (WBS) and high TG levels. Based on criteria indicating greater severity, as higher TG levels, 72 of them received empirical RIT. All remained in follow-up with their outcomes assessed. Results: Carcinoma histopathological characteristics were similar between the groups of patients. In all the assessed moments, TG levels were higher in patients who received RIT than in patients who did not receive it. Regarding WBS after RIT, 57.74% of cases showed uptake, with one-third showing evidence of distant metastasis and 23.94% with cervical uptake in remnant/recurrence of thyroid or lymph node tissue. Patients who received RIT showed a partial reduction in suppressed serum TG, while patients who did not receive RIT exhibited stability of TG during follow-up. Conclusion: After radioiodine therapy administered with biochemical evidence of metastases but without identification of iodine-avid structural disease, metastatic foci avid for iodine were identified in 57% of cases, with a subsequent reduction in serum TG, indicating a potential therapeutic benefit. Despite similar tumor histopathological characteristics, the outcomes differed between patients who received RIT and those who did not, highlighting the importance of individualizing this indication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.